EMA Moves to Enforce Clinical Trial Transparency
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- European Medicines Agency is taking what consumer advocacy groups called unexpectedly "rapid action" to ensure clinical trial results are made public as required by EU law.
- A recent analysis of the Clinical Trial Information System (CTIS) found results were reported within the required time frame for less than half of registered studies, and complete results were fully reported for only 42%.
- CTIS, created in 2022 to boost transparency across the European Union and European Economic Area, contains more than 8,400 mid- and late-stage trials.
- Researchers who conducted the first CTIS analysis said overall compliance with legal reporting requirements was weak and regulatory oversight was lacking.
- Under CTIS rules, sponsors of trials registered in the system will be legally required to post results publicly in the coming months and years.
- EMA's intervention is explicitly framed by advocacy groups as a corrective response to the analysis showing that the transparency law was not being enforced in practice.
Why it matters: With 8,400 mid- and late-stage trials in CTIS and a 42% full-results reporting rate, the EMA's enforcement push targets tens of thousands of potential missing data points that clinicians, researchers, and patients rely on — making non-compliance a legal exposure rather than a soft norm for trial sponsors operating in the EU and EEA.
